Lipoprotein-associated phospholipase A2 (Lp-PLA2): Difference between revisions
Jump to navigation
Jump to search
Brian Blank (talk | contribs) No edit summary |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Line 12: | Line 12: | ||
--> | --> | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Biomarker]] | [[Category:Biomarker]] |
Revision as of 16:54, 9 August 2012
Cardiology Network |
Discuss Lipoprotein-associated phospholipase A2 (Lp-PLA2) further in the WikiDoc Cardiology Network |
Adult Congenital |
---|
Biomarkers |
Cardiac Rehabilitation |
Congestive Heart Failure |
CT Angiography |
Echocardiography |
Electrophysiology |
Cardiology General |
Genetics |
Health Economics |
Hypertension |
Interventional Cardiology |
MRI |
Nuclear Cardiology |
Peripheral Arterial Disease |
Prevention |
Public Policy |
Pulmonary Embolism |
Stable Angina |
Valvular Heart Disease |
Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that can modify low-density lipoproteins and may be involved in atherogenesis and the risk of coronary artery disease. In a nested case-control study, patients in the highest quintile of Lp-PLA2 levels had nearly twice the odds of coronary events compared with patients in the lowest quintile.